



MATERIAL SAFETY DATA SHEET

Revision date: 28-Aug-2009

Version: 2.2

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Metronidazole 500 mg IV Infusion

Trade Name: Flagyl
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as antiprotozoal agent

2. HAZARDS IDENTIFICATION

Appearance: Pale greenish/yellow sterile solution

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:
Short Term: Ingestion of large amounts may cause central nervous system effects.
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Suspected of causing cancer.

Known Clinical Effects: Clinical use of this drug has caused peripheral neuropathy, associated with numbness and tingling of the extremities, pain, and motor weakness. Effects on blood and blood-forming organs have also occurred.

EU Indication of danger: Not classified

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Metronidazole	443-48-1	207-136-1	Xn;R40-63	0.5
Citric Acid	77-92-9	201-069-1	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Sodium Phosphate	7632-05-5	231-558-5	Not Listed	*

MATERIAL SAFETY DATA SHEET

Material Name: Metronidazole 500 mg IV Infusion
Revision date: 28-Aug-2009

Page 2 of 7
Version: 2.2

SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

MATERIAL SAFETY DATA SHEET

Material Name: Metronidazole 500 mg IV Infusion
Revision date: 28-Aug-2009

Page 3 of 7
Version: 2.2

7. HANDLING AND STORAGE

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Metronidazole	
Netherlands OEL - TWA	Listed
SODIUM CHLORIDE	
Latvia OEL - TWA	Listed
Lithuania OEL - TWA	Listed

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Metronidazole
Pfizer Occupational Exposure Band (OEB): OEB2 (control exposure to the range of >100ug/m³ to < 1000ug/m³)

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	Clear greenish/yellow
Molecular Formula:	Mixture	Molecular Weight:	Mixture

MATERIAL SAFETY DATA SHEET

Material Name: Metronidazole 500 mg IV Infusion
Revision date: 28-Aug-2009

Page 4 of 7
Version: 2.2

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Metronidazole

Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 3800 mg/kg
Mouse Intraperitoneal LD 50 870 mg/kg

SODIUM CHLORIDE

Rat Inhalation LC50/1hr > 42 g/m³
Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 4 g/kg
Rabbit Dermal LD 50 > 10 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Metronidazole

Eye Irritation Rabbit No effect

SODIUM CHLORIDE

Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

Citric Acid

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Metronidazole

2 Year(s) Mouse Oral 600 mg/kg LOAEL
80 Week(s) Rat Oral 30 mg/kg LOAEL
34 Day(s) Rat Oral = 34 g/kg LOAEL Kidney Ureter Bladder
4 Month(s) Dog Oral 75 mg/kg LOAEL
1 Year(s) Non-human Primate Oral 150 mg/kg LOAEL

Repeated Dose Toxicity Comments: Metronidazole produced tumors in mice and rats.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Metronidazole

Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Fertility

MATERIAL SAFETY DATA SHEET

Material Name: Metronidazole 500 mg IV Infusion
Revision date: 28-Aug-2009

Page 5 of 7
Version: 2.2

11. TOXICOLOGICAL INFORMATION

Reproductive & Fertility	Rabbit	Oral	200 mg/kg	NOAEL	Fertility, Developmental toxicity, Fetotoxicity
Embryo / Fetal Development	Mouse	Intraperitoneal	9 mg/kg	LOAEL	Fetotoxicity
Embryo / Fetal Development	Rat	Oral	200 mg/kg	NOEL	Not Teratogenic
Embryo / Fetal Development	Mouse	Intraperitoneal	40 mg/kg	LOAEL	Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Metronidazole

In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Positive
In Vitro Sister Chromatid Exchange Hamster Negative
In Vivo Unscheduled DNA Synthesis Rabbit Negative
In Vivo Micronucleus Rat Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Metronidazole

Not specified Rat Oral Tumors
Not specified Mouse Oral Tumors

Carcinogen Status: See below

Metronidazole

IARC: Group 2B
NTP: Listed
OSHA: Present

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Metronidazole

Mysid Shrimp OECD LC-50 96 Hours >180 mg/L
Sheepshead Minnow OECD LC-50 96 Hours >1060 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

MATERIAL SAFETY DATA SHEET

Material Name: Metronidazole 500 mg IV Infusion
Revision date: 28-Aug-2009

Page 6 of 7
Version: 2.2

14. TRANSPORT INFORMATION

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Metronidazole

California Proposition 65	Listed; Cancer
Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons:	Listed Schedule 4
EU EINECS/ELINCS List	207-136-1

Sodium Phosphate

Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	231-558-5

SODIUM CHLORIDE

Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	231-598-3

Citric Acid

Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	201-069-1

Water for Injection

Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

MATERIAL SAFETY DATA SHEET

Material Name: Metronidazole 500 mg IV Infusion
Revision date: 28-Aug-2009

Page 7 of 7
Version: 2.2

15. REGULATORY INFORMATION

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R40 - Limited evidence of a carcinogenic effect
R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet